Skip Navigation



NDT Advance Access published online on July 21, 2008

Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn407
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morales, E.
Right arrow Articles by Praga, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morales, E.
Right arrow Articles by Praga, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org



Malignant hypertension in HIV-associated glomerulonephritis

Enrique Morales1, Elena Gutierrez-Solis1, Eduardo Gutierrez1, Roberto González1, Miguel Angel Martínez2 and Manuel Praga1

1 Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain 2 Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain

Correspondence and offprint requests to: Enrique Morales, Servicio de Nefrología, Hospital 12 de Octubre, Avda, Andalucía s/n, 28041 Madrid, Spain. Tel: +34-91390-8208; Fax: +34-91390-8393; E-mail: emoralesr{at}senefro.org



  Abstract

Background. Glomerular diseases other than HIVAN (HIV-associated nephropathy) are common among HIV patients but the information about their clinical characteristics and prognosis is very scarce. We have observed several HIV patients with glomerulonephritis in whom malignant hypertension (MHT) was the first clinical manifestation.

Methods. All HIV-infected individuals with a biopsy-proven glomerulonephritis at our hospital were reviewed. Information about clinical characteristics, histopathologic data and outcome was collected. The incidence of MHT among HIV and non-HIV patients with glomerulonephritis was studied.

Results. Thirty HIV patients with glomerulonephritis were identified. Ten of them (33%) presented with MHT (severe hypertension and grade III hypertensive retinopathy). In comparison with patients without MHT, they showed a significantly higher blood pressure at presentation, a higher finding of IgA nephropathy (50% versus 15%; P < 0.05) and of malignant nephrosclerosis (60% versus 0%; P < 0.05) in renal biopsies, a higher viral load and a lower CD4+ cell count at the end of follow-up and a worse patient and renal survival: six patients (60%) started chronic dialysis and seven (70%) died after a follow-up of 11.8 ± 16.2 and 39 ± 35 months, respectively. Co-infection by HCV (hepatitis C virus) and HBV (hepatitis B virus) was very frequent among patients with malignant hypertension. The incidence of malignant hypertension among non-HIV patients with glomerulonephritis was significantly lower than that among HIV-infected patients.

Conclusions. Malignant hypertension is a common presentation of patients with HIV-associated glomerulonephritis, particularly in those with IgA nephropathy, and is associated with a very poor patient and renal survival.

Keywords: malignant hypertension; HIV-associated glomerulonephritis; IgA nephropathy; HCV infection; glomerular disease

Received for publication: 14. 5.08
Accepted in revised form: 26. 6.08


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.